Cloning Open Reading Frame (ORF) of Rv2430c Mycobacterium tuberculosis Indonesian Isolate in Escherichia coli JM 109
Rosana Agus1,, Muhammad Nasrum Massi2, Francisca Srioetami Tanoerahardjo3
1Department Of Biology, Faculty of Life Sciences, Hasanuddin University, Indonesia
2Department of Microbiology, Faculty of Medicine, Hasanuddin University, Indonesia
3Development Ministry of Health of Republic of Indonesia, Central Basic Biomedical, Health Technology National Institute of Health and Research, Indonesia
Abstract | |
1. | Introduction |
2. | Materials and Methods |
3. | Results and Discussion |
4. | Conclusion |
Acknowledgments | |
References |
Abstract
Various strategies have been implemented to prevent tuberculosis. Vaccination with Bacille Calmette Guerin (BCG) vaccine is still used around the world. Generally, most people in have gained BCG vaccine as an infant, but the effectiveness of these vaccines do not survive to adulthood. Therefore, the necessary replacement BCG vaccine more effective to eliminate tuberculosis. Mycobacterium tuberculosis is an intracellular pathogen and it was inside the macrophage, which is considered to be the most important component of the immune system. M. tuberculosis has two sets of genes are highly polymorphic referred to as PE and PPE families. These unique families of proteins account for about 10% of the mycobacterial genome and have attracted great interest from a variety of different studies around the world. One member of the as a vaccine candidate is Rv 2430c. It is known that the sera of all patients infected with TB showed strong antibody responses against Rv 2430c compared to healthy individuals. The existence of these antibodies indicates that this protein is found in vivo during infection and is a native immunogenic molecule. The purpose of this study was to clone the Open Reading Frame (ORF) Rv 2430c M. tuberculosis Indonesian isolates to host cells Esherichia coli JM 109. The method used is by isolating -chromosomal DNA from clinical isolates from Indonesia, amplifying the ORF Rv 2430c with , ligating into cloning vectors pGEM-T and transform to E.coli JM 109. Characterization of clones do with migration analysis, restriction analysis and . The results obtained are recombinant clones that carry insertion was Rv 2430cKeywords: Mycobacterium tuberculosis, Rv 2430c, ORF, , JM 109.
Keywords: mycobacterium tuberculosis, Rv 2430c, vaccine
Copyright © 2016 Science and Education Publishing. All Rights Reserved.Cite this article:
- Rosana Agus, Muhammad Nasrum Massi, Francisca Srioetami Tanoerahardjo. Cloning Open Reading Frame (ORF) of Rv2430c Mycobacterium tuberculosis Indonesian Isolate in Escherichia coli JM 109. American Journal of Biomedical Research. Vol. 4, No. 4, 2016, pp 99-101. https://pubs.sciepub.com/ajbr/4/4/4
- Agus, Rosana, Muhammad Nasrum Massi, and Francisca Srioetami Tanoerahardjo. "Cloning Open Reading Frame (ORF) of Rv2430c Mycobacterium tuberculosis Indonesian Isolate in Escherichia coli JM 109." American Journal of Biomedical Research 4.4 (2016): 99-101.
- Agus, R. , Massi, M. N. , & Tanoerahardjo, F. S. (2016). Cloning Open Reading Frame (ORF) of Rv2430c Mycobacterium tuberculosis Indonesian Isolate in Escherichia coli JM 109. American Journal of Biomedical Research, 4(4), 99-101.
- Agus, Rosana, Muhammad Nasrum Massi, and Francisca Srioetami Tanoerahardjo. "Cloning Open Reading Frame (ORF) of Rv2430c Mycobacterium tuberculosis Indonesian Isolate in Escherichia coli JM 109." American Journal of Biomedical Research 4, no. 4 (2016): 99-101.
Import into BibTeX | Import into EndNote | Import into RefMan | Import into RefWorks |
At a glance: Figures
1. Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is responsible for 9 million new cases of active TB and 1–1.5 million deaths annually [1]. It is estimated that nearly 2 billion people suffer from latent TB around the world, which potentially become an active TB. The only vaccine currently used is BCG, which has been developed since almost a century ago. BCG is given in newbornes routinely in TB endemic countries. However, the effectiveness of BCG was reduced in adolescents, and the vaccine does not consistently prevent the development of active pulmonary TB in adults (efficacy estimated between 0 and 80% with the lowest efficacy rates often found in countries with the highest burden of TB) [2, 3, 4]. Thus, there is an urgent need for a new TB vaccine to either boost immunity primed by BCG or replace BCG [5, 6].
The variation in sequence and length of C-terminal region among members of the unique PE (Pro-Glu) and (Pro-Pro-Glu) protein families of Mycobacterium tuberculosis is a likely source of antigenic variation. Based on in-silico analysis, we selected a hypothetical open reading frame (ORF) encoding a protein belonging to the family and having epitopes with predictably higher antigenic indexes. Reverse transcriptase from in vitro-cultured M. tuberculosis H37Rv generated an mRNA product corresponding to this gene, which is indicating the expression of this ORF (Rv2430c) at the mRNA level. Our results reveal that this ORF induces a strong B-cell response compared to that generated by M. tuberculosis Hsp10 or , pointing to the immunodominant nature of the protein [7].
Cloning of ORF Rv 2430 performed on pGEM-T cloning vector and host Escherichia. coli JM 109. It is expected that this gene can be used as candidate antigens for TB vaccine search.
2. Materials and Methods
2.1. Bacterial Strains and PlasmidsThe cloning vectors pGEM-T Easy (Promega) was used. The strains M. tuberculosis was obtained from clinical isolate from Indonesia. E. coli JM 109 was obtained from Center For Biomedical and Basic Technology of Health.
2.2. Culture ConditionThe E. coli JM 109 were incubate with stirring over night in LB medium in the presence of ampicillin (1μg/ml) at 37°C. E.coli JM109 competent cells prepared in advance by the CaCl2 method [8] modified.
2.3. PCRThe following primer was design by [7]
Rev 5’-AAGCTTCTAAGTGTCTGTACGCGATGA-3’
Fwd 5’-GGATCCATGCATTTCGAAGCGTAC-3’
The reactions were performed with 1 μl of template in a total volume of 25 μl. Generally, the profiles consisted of a hot start at 94°C, an initial denaturation at 94°C for 1 minute, a denaturation at 94°C for 30 second, an annealing at 55°C for 1 minute and an extension step at 72°C for 40 second. After 25 cycles an extension was carried out at 72°C for 7 minutes. products were examined by agarose gel electrophoresis and staining with ethidium bromide.
2.4. TransformationIsolation of DNA and transformation of the E. coli JM 109 cells were performed as described in the guidebook [8], with the following modifications. Transformed cells were spread on the appropriate indicator plates containing ampicillin. Colonies were scored for phenotype on Luria Bertani agar plates after 24 hours at 37°C.
2.5. Creation of Plasmids of the Recombinant Rv 2430c in E. coli JM 109Fragment of the ORF Rv 2430c were obtained by using two primers pair and DNA of the M. tuberculosis Indonesian strain as a template. The pGEM-T vector and PCR product were cut with BamHI and HindIII, mixed, and treated with T4 DNA ligase. The resulting recombinant plasmid pGEM-T-Rv2430c was transformed in E. coli JM 109.

3. Results and Discussion
3.1. PCR Product and PurificationThe results of amplification of ORF Rv 2430 observed by electrophoresis agarosa. A band was revealed which corresponded to the gene with the apparent of 597 bp. It is appropriate that obtained Choudhary et al, 2003 that 597bp band was observed upon staining with ethidium bromide, indicating that the ORF was expressed at the mRNA level in the liquid cultures of M. tuberculosis

Isolation of plasmid were performed according to the procedure instructions (BioRad). Characterization was done by migration analysis, restriction analysis, and PCR analysis. Migration analysis was done by comparing pGEM-T (3000bp) and pGEM-T-Rv 2430c (3597bp). A band shows difference length while pGEM-T-Rv2430c had slower migration than pGEM-T (Figure 3).

This suggests that the plasmid without insert (pGEM-T) will move faster than the recombinant plasmid (pGEM-T-Rv 2430). This means that the inserts ORF Rv 2430 has been successfully ligation into the vector pGEM-T.
Restriction analysis was done using 2 restriction enzymes BamHI and HindIII in pGEM-T-Rv2430c. By electrophoresis, a linier band was showed a different shape with uncut recombinant plasmid which has supercoiled and relaxed band (Figure 4).

Uncut plasmids can be in two forms: relaxed and supercoiled (or superhelical). The lane with the digested plasmid has a single band, while the lane with the undigested sample has three bands. If the lower band had moved most rapidly because it was a smaller fragment than the others, then we would expect that it would be much dimmer than the others because, in general, less fluorescent dye is intercolated by smaller fragments. However, in this case the lower band is much brighter than the other bands, either because the supercoiled shape holds dye better or because a higher fraction of the molecules in that lane were in the supercoiled form than in other forms [9].
analysis was done by using exactly the same cycle as it mentioned before for amplified the Rv 2430c gene. Electrophoresis showed that plasmid recombinant pGEM-T-Rv2430c contain the Rv 2430c gene as DNA insert was 597 bp (Figure 5).

4. Conclusion
Cloning ORF of Rv 2430c M. tuberculosis Indonesia isolates to Escherichia coli JM 109 has been successfully and characterized insert by , migration analysis and restriction analysis.
Acknowledgments
The authors would like to thank Kemenristek Dikti and Center for Biomedical and Basic Technology of Health, which has funded this research through a Consortium of TB Vaccine.
References
[1] | World Health Organization. Global tuberculosis report, World Health Organization, Geneva, 2013. | ||
![]() | |||
[2] | Abubakar, I., L. Pimpin, C. Ariti, R. Beynon, P. Mangtani, J. A. Sterne, P. E. Fine, P. G. Smith, M. Lipman, D. Elliman, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gue´rin vaccination against tuberculosis. Health Technol. Assess.17: 1-372, v–vi, 2013. | ||
![]() | |||
[3] | Hart, P. D., and I. Sutherland. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 2: 293-295, 1977 | ||
![]() | View Article PubMed | ||
[4] | Baily, G. V. 1980. Tuberculosis prevention Trial, Madras. Indian J. Med. Res. 72 (Suppl.): 1-74, 1980. | ||
![]() | PubMed | ||
[5] | Brennan, M. J., and J. Thole. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb.) 92(Suppl. 1): S6-S13, 2012. | ||
![]() | View Article | ||
[6] | Checkley, A. M., and H. McShane. Tuberculosis vaccines: progress and challenges. Trends Pharmacol. Sci. 32: 601-606, 2011. | ||
![]() | View Article PubMed | ||
[7] | Choudhary R.K, Sangita Mukhopadhyay, Prachee Chakhaiyar, Naresh Sharma, K.J.R Murthy, V.M Katoch and Seyed E. Hasnain, PPE antigen Rv 2430 c of Mycobacterium tuberculosis induces a strong B- cell Response, Infection and Immunity, Vol 71 No 11, p.6338-6343, 2003. | ||
![]() | View Article PubMed | ||
[8] | Sambrook, J., Fristch, E.F. dan Maniatis, T. Molecular Cloning A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989. | ||
![]() | |||
[9] | Jean and Alexander Heard Library, 2016, BSCI 1510l: Detecting uncut Plasmids from the Restriction Digests. | ||
![]() | |||